The Incretin Mirage: Epigenetic Memory as a Potential Driver of Post-Treatment Weight Regain.

While incretin receptor agonists deliver profound weight loss, clinical data reveal a consistent challenge: treatment discontinuation routinely triggers rapid weight regain. We define this phenomenon as the "Incretin Mirage"-a state where pharmacologically induced weight reduction temporarily conceals the persistent metabolic and neuroendocrine adaptations established during chronic obesity. Despite a lower body mass, key drivers of the disease, including adipocyte dysfunction and altered appetite signaling, retain a molecular imprint of obesity driven by persistent epigenetic marks. To explain why the body aggressively resists sustained weight loss after treatment cessation, we introduce the "Epigenetic Detent." This novel conceptual mechanism links adipocyte epigenetic memory with neuroendocrine plasticity to preserve a high-adiposity set-point. Consequently, the moment pharmacological suppression is lifted, this persistently defended set-point serves as a potential driver of weight regain. Achieving a durable therapeutic response therefore requires moving beyond transient appetite suppression. We advocate for a coordinated, multi-tiered strategy that couples lifestyle and environmental restructuring with next-generation epigenetic therapies capable of erasing these cellular marks and achieving a complete cellular metabolic reset.